Economic evaluation of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices (PINCER)
暂无分享,去创建一个
A. Sheikh | R. Prescott | K. Cresswell | J. Hippisley-Cox | D. Kendrick | K. Putman | S. Murray | M. Franklin | A. Avery | S. Rodgers | A. Avery | J. Cantrill | C. Morris | M. Eden | L. Annemans | L. Tuersley | Y. Vinogradova | R. Howard | S. Armstrong | Glen Swanwick | R. Elliott | M. Boyd | N. Verhaeghe | J. Hayre | T. Turner | V. Vinogradova | T. Turner | A. Sheikh
[1] B. Strohmer,et al. Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism , 2008, Wiener klinische Wochenschrift.
[2] J. Rey,et al. Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. , 2004, The American journal of medicine.
[3] S. Morant,et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use , 1997, Alimentary pharmacology & therapeutics.
[4] R. Elliott. Is QUM an Efficient Use of Healthcare Resources? , 2008 .
[5] H. Sørensen,et al. Outcome of peptic ulcer bleeding among users of traditional non‐steroidal anti‐inflammatory drugs and selective cyclo‐oxygenase‐2 inhibitors , 2006, Alimentary pharmacology & therapeutics.
[6] D. Symmons,et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. , 2006, Health technology assessment.
[7] T. Brennan,et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. , 1991, The New England journal of medicine.
[8] Dennis A. Revicki,et al. Costs of Bipolar Disorder , 2012, PharmacoEconomics.
[9] L. Sharples,et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. , 2006, Health technology assessment.
[10] Miranda R Andrus,et al. Use of β-Blockers in Patients with COPD , 2004 .
[11] H. Collard,et al. A practical guide for clinicians who treat patients with amiodarone: 2007. , 2007, Heart rhythm.
[12] Aziz Sheikh,et al. Protocol for the PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices , 2009, Trials.
[13] J. Dowie. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. , 2004, Health economics.
[15] D W Bates,et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[16] F. Kapczinski,et al. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[17] H. Sørensen,et al. 30-Day Mortality After Peptic Ulcer Perforation Among Users of Newer Selective Cox-2 Inhibitors and Traditional NSAIDs: A Population-Based Study , 2006, The American Journal of Gastroenterology.
[18] J. Schwartz,et al. Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. , 2000, Rheumatology.
[19] C. Haffajee,et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. , 1984, Annals of internal medicine.
[20] P. Cullinan,et al. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. , 1999, Circulation.
[21] N Hurwitz,et al. Admissions to Hospital due to Drugs , 1969, British medical journal.
[22] G. Mooney. What else do we want from our health services? , 1994, Social Science & Medicine (1967).
[23] R. Rosenfeld,et al. Authority , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[24] O. Bugnon,et al. The Nine-Year Sustained Cost-Containment Impact of Swiss Pilot Physicians-Pharmacists Quality Circles , 2010, The Annals of pharmacotherapy.
[25] L. Braverman,et al. The effects of amiodarone on the thyroid. , 2001, Endocrine reviews.
[26] Magnus Johannesson,et al. Swedish population health-related quality of life results using the EQ-5D , 2004, Quality of Life Research.
[27] S. Nurko. At what level of hyperkalemia or creatinine elevation should ACE inhibitor therapy be stopped or not started? , 2001, Cleveland Clinic journal of medicine.
[28] Jan Scott,et al. Nonadherence with mood stabilizers: prevalence and predictors. , 2002, The Journal of clinical psychiatry.
[29] Y. Hassan,et al. Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases , 2009, Pharmacy World & Science.
[30] A. Egberts,et al. Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] S B Soumerai,et al. Principles of educational outreach ('academic detailing') to improve clinical decision making. , 1990, JAMA.
[32] A. El‐Solh,et al. Clinical factors associated with hyperkalemia in patients with congestive heart failure 1 , 2005 .
[33] D. Scott,et al. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. , 2005, Rheumatology.
[34] A. Ducharme,et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. , 2006, American heart journal.
[35] D. Bates,et al. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. , 2003, Archives of internal medicine.
[36] M. Picot,et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. , 1997, British journal of rheumatology.
[37] C. Brunia,et al. Wait and see. , 2001, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.
[38] R. Ogilvie,et al. An educational program in digitalis therapy , 1973 .
[39] Vahram Ghushchyan,et al. Mapping the EQ-5D Index from the SF-12: US General Population Preferences in a Nationally Representative Sample , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[40] David W. Bates,et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group , 1997 .
[41] G. Devereux,et al. Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma. , 1998, British journal of clinical pharmacology.
[42] Brian J Lipworth,et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study , 2011, BMJ : British Medical Journal.
[43] C. Ohmann,et al. Time-trends in the epidemiology of peptic ulcer bleeding , 2005, Scandinavian journal of gastroenterology.
[44] Anthony J Avery,et al. Incidence and Possible Causes of Prescribing Potentially Hazardous/Contraindicated Drug Combinations in General Practice , 2005, Drug safety.
[45] D. Georgopoulos,et al. Influence of pindolol on asthmatics and effect of bronchodilators. , 1986, Respiration; international review of thoracic diseases.
[46] J. Franklyn,et al. Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? , 2002, The Journal of clinical endocrinology and metabolism.
[47] W. Shen,et al. Implication of serum concentration monitoring in patients with lithium intoxication , 2004, Psychiatry and clinical neurosciences.
[48] A. Young,et al. Lithium in maintenance therapy for bipolar disorder , 2006, Journal of psychopharmacology.
[49] Shepley Orr,et al. Does responsibility affect the public's valuation of health care interventions? A relative valuation approach to health care safety. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[50] Bertram Pitt,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.
[51] C. Asche,et al. Rates of Hospitalizations and Emergency Department Visits in Patients with Asthma and Chronic Obstructive Pulmonary Disease Taking β‐Blockers , 2007, Pharmacotherapy.
[52] D. Farley,et al. Surgical Management of Amiodarone-associated Thyrotoxicosis: Mayo Clinic Experience , 2004, World Journal of Surgery.
[53] V. Pettilä,et al. Survival and quality of life of patients requiring acute renal replacement therapy , 2005, Intensive Care Medicine.
[54] R. Ward,et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. , 1984, American journal of ophthalmology.
[55] R. Rapanà,et al. Acute renal failure of medical type in an elderly population. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[56] R. Ogilvie,et al. Adverse drug reactions during hospitalization. , 1967, Canadian Medical Association journal.
[57] J. Le Heuzey,et al. A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study , 2010, Journal of cardiovascular electrophysiology.
[58] Jonathan M. Teich,et al. Identifying hospital admissions due to adverse drug events using a computer‐based monitor , 2001, AMIA.
[59] E. Israel,et al. Treatment with β blockers in people with COPD , 2011, BMJ : British Medical Journal.
[60] Gustavo A. Cardenas,et al. Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies. , 2003, Cleveland Clinic journal of medicine.
[61] A. Sheikh,et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis , 2012, The Lancet.
[62] Sigall K. Bell,et al. Guilty, afraid, and alone--struggling with medical error. , 2007, The New England journal of medicine.
[63] D. Conen,et al. Clinical Course and Predictors of Outcome , 2007 .
[64] C. Bombardier,et al. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. , 1998, Arthritis and rheumatism.
[65] B. Palmer. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.
[66] David J McLernon,et al. Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[67] A Rastergar,et al. A Practical Guide for Medical Teachers. , 2002, Postgraduate medical journal.
[68] C. Hawkey,et al. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors , 2003, Gut.
[69] W. Encinosa,et al. The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients , 2010, PharmacoEconomics.
[70] M Sculpher,et al. Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines. , 2000, Family practice.
[71] P. Laurberg,et al. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. , 1998, The Journal of clinical endocrinology and metabolism.
[72] G. Daniels. Amiodarone-induced thyrotoxicosis. , 2001, The Journal of clinical endocrinology and metabolism.
[73] D. Macpherson,et al. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? , 1998, Archives of internal medicine.
[74] N. Maniadakis,et al. Health-related quality of life measurement in patients admitted with coronary heart disease and heart failure to a cardiology department of a secondary urban hospital in Greece. , 2008, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[75] M Sculpher,et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.
[76] A. Pinchera,et al. Proportion of type 1 and type 2 amiodarone‐induced thyrotoxicosis has changed over a 27‐year period in Italy , 2007, Clinical endocrinology.
[77] B. Lipworth,et al. Response to salbutamol in patients with mild asthma treated with nadolol , 2010, European Respiratory Journal.
[78] A. Weetman,et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy , 1998, Heart.
[79] I. Klein,et al. Thyroid hormone and the cardiovascular system. , 1997, The New England journal of medicine.
[80] David Lester,et al. Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? , 2008, Neuropsychiatric disease and treatment.
[81] Rainu Kaushal,et al. Analysis of Medication-Related Malpractice Claims: Causes, Preventability, and Costs , 2003 .
[82] P. Blakely,et al. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers , 2009, Therapeutics and clinical risk management.
[83] C. Isles,et al. Potassium disorders--clinical spectrum and emergency management. , 2006, Resuscitation.
[84] A. Gray. Adverse events and the National Health Service : an economic perspective a report to the National Patient Safety Agency , 2005 .
[85] A. B. Hall,et al. The sequencing of medication administration in the management of hyperkalemia. , 2009, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.
[86] D. Goldfarb,et al. Indications for hospitalization of patients with hyperkalemia. , 2000, Archives of internal medicine.
[87] Matthew Labreche,et al. Anticoagulation-associated adverse drug events. , 2011, The American journal of medicine.
[88] Amanda J Lee,et al. Characterisation and comparison of health-related quality of life for patients with renal failure , 2005, Current medical research and opinion.
[89] H. Fabel,et al. [Changes in lung function following administration of eyedrops containing timolol, metipranolol, pindolol and pilocarpine in healthy probands and patients with mild bronchial asthma]. , 1987, Klinische Wochenschrift.
[90] K. Harjai,et al. Effects of Amiodarone on Thyroid Function , 1997, Annals of Internal Medicine.
[91] A. Berghöfer,et al. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients , 1999, Psychiatry Research.
[92] S. K. Narayana,et al. Management of amiodarone-related thyroid problems , 2011, Therapeutic advances in endocrinology and metabolism.
[93] P. Donnan,et al. Prescribing of β-adrenoceptor antagonists in asthma: an observational study , 2011, Thorax.
[94] A. Majeed,et al. Routinely recorded patient safety events in primary care: a literature review. , 2012, Family practice.
[95] G. Dunn,et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. , 2007, Health technology assessment.
[96] D. Symmons,et al. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? , 2006, Rheumatology.
[97] B. Palmer. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[98] Sang-Woong Han,et al. Therapeutic Approach to Hyperkalemia , 2002, Nephron.
[99] R. Warburton,et al. Patient safety--how much is enough? , 2005, Health policy.
[100] R. Baldessarini,et al. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients , 2009, Epidemiologia e Psichiatria Sociale.
[101] J. Franklyn,et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. , 1998, The New England journal of medicine.
[102] D. Bates,et al. The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .
[103] E. Ziegel,et al. Root Cause Analysis , 2010, Journal of Clinical Engineering.
[104] D. Conen,et al. Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. , 2007, Journal of the American College of Cardiology.
[105] Guy Goodwin,et al. Recurrence of Mania after Lithium Withdrawal , 1994, British Journal of Psychiatry.
[106] R. Chadda,et al. Therapeutic Drug Monitoring of Lithium in Patients With Bipolar Affective Disorder: Experiences From a Tertiary Care Hospital in India , 2009, American Journal of Therapeutics.
[107] F. Bogazzi,et al. Approach to the patient with amiodarone-induced thyrotoxicosis. , 2010, The Journal of clinical endocrinology and metabolism.
[108] Jim Smith,et al. Building a safer NHS for patients: improving medication safety , 2004 .
[109] A. Berghöfer,et al. The Impact of Lithium Long-Term Medication on Suicidal Behavior and Mortality of Bipolar Patients , 2005, Archives of suicide research : official journal of the International Academy for Suicide Research.
[110] M. Buxton,et al. Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy , 2007, The European Journal of Health Economics.
[111] J. Reason. Human error: models and management , 2000, BMJ : British Medical Journal.
[112] S. Thompson,et al. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.
[113] N. Pannu,et al. Methodological considerations for observational studies of acute kidney injury using existing data sources. , 2009, Journal of nephrology.
[114] E. Vieta,et al. Evolving trends in the long-term treatment of bipolar disorder , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[115] D. Malatjalian,et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. , 1996, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[116] D. Suh,et al. Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients , 2000, The Annals of pharmacotherapy.
[117] L. Steuten,et al. Economic evaluation of healthcare safety: which attributes of safety do healthcare professionals consider most important in resource allocation decisions? , 2010, Quality and Safety in Health Care.
[118] R. Rodriguez-Monguio,et al. Assessing the Economic Impact of Adverse Drug Effects , 2012, PharmacoEconomics.
[119] M. Gossop,et al. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). , 2004, Addiction.
[120] C. Barbosa,et al. Methodological assessment of economic evaluations of alcohol treatment: what is missing? , 2010, Alcohol and alcoholism.
[121] P. Ladenson,et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. , 1995, JAMA.
[122] S. Srinathan,et al. Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists , 2008, The British journal of dermatology.
[123] P. Laurberg,et al. Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. , 1999, Thyroid : official journal of the American Thyroid Association.
[124] A. O’Sullivan,et al. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. , 2006, European journal of endocrinology.
[125] A. Sheikh,et al. PINCER trial: a cluster randomised trial comparing the effectiveness and cost-effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices , 2010 .
[126] D. Classen,et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.
[127] H. Krumholz,et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. , 2001, Journal of the American College of Cardiology.
[128] Andrew H. Briggs,et al. Development of an Economic Model to Assess the Cost Effectiveness of Asthma Management Strategies , 2012, PharmacoEconomics.
[129] J. Franklyn,et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. , 2010, JAMA.
[130] A. El‐Solh,et al. Clinical factors associated with hyperkalemia in patients with congestive heart failure. , 2005, Journal of clinical pharmacy and therapeutics.
[131] D. Bates,et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.
[132] F. Gobel,et al. Effect of propranolol on respiratory function and exercise tolerance in patients with chronic obstructive lung disease. , 1975, Chest.
[133] R. Harris,et al. Potential side effects of renin inhibitors – mechanisms based on comparison with other renin–angiotensin blockers , 2006, Expert opinion on drug safety.
[134] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[135] D. Buss,et al. Iodine in British foods and diets , 1994, British Journal of Nutrition.
[136] B. Dimond. The National Patient Safety Agency , 2001 .
[137] S. Royal,et al. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis , 2006, Quality and Safety in Health Care.
[138] P. Mitchell,et al. Maintenance treatments for bipolar disorders , 2007 .
[139] World federation of societies of biological psychiatry , 1990, Biological Psychiatry.
[140] W. Wiersinga,et al. Diagnosis and management of amiodarone‐induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association , 2004, Clinical endocrinology.
[141] U. Haustein,et al. Methotrexate in psoriasis: 26 years’ experience with low‐dose long‐term treatment , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.
[142] M. Pirmohamed,et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.
[143] W. Wiersinga,et al. Diagnosis and management of amiodarone‐induced thyrotoxicosis: similarities and differences between North American and European thyroidologists * , 2008, Clinical endocrinology.
[144] J. Nolan,et al. Case-finding for unsuspected thyroid disease: costs and health benefits. , 1985, American journal of clinical pathology.
[145] Tim Straughan,et al. NHS Information Centre , 2008 .
[146] N. Devlin,et al. QA4 IS THE AIM OF THE HEALTH CARE SYSTEM TO MAXIMISE QALYS? AN INVESTIGATION OF ‘WHAT ELSE MATTERS’ IN THE NHS , 2011 .
[147] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold Depressions , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[148] David O. Taylor,et al. Can patients with COPD or asthma take a beta-blocker , 2010, Cleveland Clinic Journal of Medicine.
[149] David W Bates,et al. The Costs Associated With Adverse Drug Events Among Older Adults in the Ambulatory Setting , 2005, Medical care.
[150] W. Waring,et al. Pattern of lithium exposure predicts poisoning severity: evaluation of referrals to a regional poisons unit. , 2007, QJM : monthly journal of the Association of Physicians.
[151] K. Loh. Amiodarone-induced thyroid disorders: a clinical review , 2000, Postgraduate medical journal.
[152] J. Franklyn,et al. Successful Treatment of Amiodarone-Induced Thyrotoxicosis , 2002, Circulation.
[153] A. Hoes,et al. Amiodarone‐induced thyroid dysfunction associated with cumulative dose , 2002, Pharmacoepidemiology and drug safety.
[154] M. Schott. Amiodarone-Induced Thyrotoxicosis Is a Predictor of Adverse Cardiovascular Outcome , 2009 .
[155] L. Laine,et al. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006 .
[156] A. B. Prasad,et al. British National Formulary , 1994 .
[157] A. Gamma,et al. Suicide in 406 Mood-Disorder Patients With and Without Long-Term Medication: A 40 to 44 Years' Follow-Up , 2005, Archives of suicide research : official journal of the International Academy for Suicide Research.
[158] J. Karnon,et al. Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). , 2009, Journal of evaluation in clinical practice.
[159] P. Macdonald,et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[160] J. Thorp,et al. Effects of oxprenolol on the airways of normal and bronchitic subjects , 1976, European Journal of Clinical Pharmacology.
[161] A. Egberts,et al. Adverse drug events in hospitalized patients A comparison of doctors, nurses and patients as sources of reports , 1999, European Journal of Clinical Pharmacology.
[162] James M Robins,et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.
[163] E. Salpeter,et al. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. , 2002, Annals of internal medicine.
[164] L. Niskanen,et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.
[165] K. Jamison,et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of psychiatry.
[166] J. Chanard,et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. , 1998, American journal of hypertension.
[167] J. Kellum,et al. Acute kidney injury: epidemiology and diagnostic criteria , 2006, Current opinion in critical care.
[168] Arl Medford,et al. British Thoracic Society , 2004 .
[169] Silas Martin,et al. Patient-based utilities for bipolar disorder-related health states. , 2005, Journal of affective disorders.
[170] Julia A. Kelleher,et al. Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial. , 2005, Archives of internal medicine.
[171] J. Avorn,et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) , 1999, American heart journal.
[172] D A Revicki,et al. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. , 1998, Journal of affective disorders.
[173] L. Kohn,et al. To Err Is Human : Building a Safer Health System , 2007 .
[174] B. Pitt. ACE Inhibitors in Heart Failure: Prospects and Limitations , 1997, Cardiovascular Drugs and Therapy.
[175] R. Fleming. Equity and Excellence: liberating the NHS , 2010 .
[176] S. Cantor,et al. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. , 2001, Surgery.
[177] J. E. Hansen,et al. beta-Adrenergic blockade with pindolol (LB-46) in mild to moderate asthma. , 1981, Chest.
[178] S. Yusuf,et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .
[179] M. Johannesson,et al. Patients' willingness to pay for autologous blood donation. , 1997, Health policy.
[180] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[181] R. Tallis,et al. PRESCRIPTION OF CONTRAINDICATED AND INTERACTING DRUGS IN ELDERLY PATIENTS ADMITTED TO HOSPITAL , 1984, The Lancet.
[182] Rainu Kaushal,et al. Technology Evaluation: Return on Investment for a Computerized Physician Order Entry System , 2006, J. Am. Medical Informatics Assoc..
[183] R. Califf,et al. Economic effects of beta-blocker therapy in patients with heart failure. , 2004, The American journal of medicine.
[184] M. Weinstein,et al. What Do Patients Value?: Willingness to Pay for Ultrasound in Normal Pregnancy , 1985, Medical care.
[185] B. Lipworth,et al. Think the impossible: beta-blockers for treating asthma. , 2009, Clinical science.
[186] B. Psaty,et al. Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[187] L. Laine,et al. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006, The American journal of medicine.
[188] E. Salpeter,et al. Cardioselective -Blockers in Patients with Reactive Airway Disease , 2002, Annals of Internal Medicine.
[189] James Nguyen,et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[190] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .
[191] A. Gray. Adverse events and the National Health Service: an economic perspective , 2003 .
[192] S. Palmer,et al. Cost-utility of a disease management program for patients with asthma , 2007, International Journal of Technology Assessment in Health Care.
[193] F. Bogazzi,et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. , 2009, The Journal of clinical endocrinology and metabolism.
[194] A. Waldo. Thyroid Function Abnormalities during Amiodarone Therapy for Persistent Atrial Fibrillation , 2008 .
[195] D. Au. Use of β blockers in patients with COPD , 2008, Thorax.
[196] Robert J Volk,et al. Psychological benefits of prostate cancer screening: the role of reassurance , 2002, Health expectations : an international journal of public participation in health care and health policy.
[197] J. Saurat,et al. Impact of adalimumab treatment on health‐related quality of life and other patient‐reported outcomes: results from a 16‐week randomized controlled trial in patients with moderate to severe plaque psoriasis , 2007, The British journal of dermatology.
[198] S. Hernández-Díaz,et al. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. , 2000, Archives of internal medicine.
[199] P J Schneider,et al. Cost of medication-related problems at a university hospital. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[200] Elisabeth Fenwick,et al. A guide to cost-effectiveness acceptability curves. , 2005, The British journal of psychiatry : the journal of mental science.
[201] T A Brennan,et al. The Institute of Medicine report on medical errors--could it do harm? , 2000, The New England journal of medicine.
[202] B J O'Brien,et al. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.
[203] M. Iseman,et al. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. , 1986, The American review of respiratory disease.